350 rub
Journal №6 for 2013 г.
Article in number:
Novel drugs and therapies for the treatment of tuberculosis
Keywords: tuberculosis multi-drug-resistant tuberculosis extensively drug-resistant tuberculosis new drugs fluoroquinolones nitroimizadole antibiotics linezolid
Authors:
A. Karchevskaya
Abstract:
This article is an overview. It introduces novel drugs and ways of treatment, especially making new combinations of drugs, for the treatment of tuberculosis. The article discusses different drugs and the mechanism of their action whenever possible.
Pages: 20-23
References
  1. O-Grady J., Maeurer M., Mwaba P. et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr. Opin. Pulm. Med. 2011. V. 17. P. 134-141.
  2. Jeon C., Harries A., Baker M. et al. Bi-directional screening for tuberculosis and diabetes: a systematic review // Tropical Medicine and International Health. 2010. V. 15. P. 1300-1314.
  3. Zumla A., Raviglione M., Hafner R. et al. Tuberculosis // N. Engl. J. Med. 2013. V. 368. P. 745-55.
  4. Chang K., Yew W., Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses // Antimicrobial Agents and Chemotherapy. 2011. V. 55. P. 4449-4505.
  5. Lienhardt C., Glaziou P., Uplekar M. et al. Global tuberculosis control: lessons learnt and future prospects. Nature reviews. Microbiology. 2012. V. 10. P. 407-416.
  6. Minion J., Pai M. Bacteriophage assays for rifampicin resistance detection in Mycobacterium tuberculosis: updated meta-analysis // Int. J. Tuberc. Lung. Dis. 2010. V. 14. № 8. P. 941-951.
  7. Gaminero J., Sotgiu G., Zumla A. et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis // Lancet Infect. Dis. 2010. V. 10. 621-629.
  8. World health organization global tuberculosis report. 2012. ISBN 978 92 4 156450 2.
  9. Pai M., Minion J., Sohn H. et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges // Clin. Chest. Med. 2009. V. 30. P. 701-716.
  10. Lienhardt C., Vernon A., Raviglione M. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes // Curr. Poin. Pulm. Med. 2010. V. 16. V. 186-193.
  11. Chen H., Yu M., Huang W. et al. Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis // J. Clin. Microbiol. 2012. V. 50. № 6. P. 2085-2088.
  12. Baciewicz A., Chrisman C., Finch C. et al. Update on rifampin and rifabutin drug interactions // Arch. Intern. Med. 2002. V. 162. P. 126-136.
  13. Sterling T., Villarino M., Borisov A. et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection // N. Engl. J. Med. 2011. V. 365. № 23. P. 2155-2166.
  14. Dorman S., Goldberg S., Stout J. et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium // JID. 2012. V. 206. № 7. P. 1030-40.
  15. Zaunbrecher M., Sikes R., Metchock B. et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferaseeis confers kanamycin resistance in Mycobacterium tuberculosis // PNAS. 2009. V. 106. № 47. P. 20004-20009.
  16. Sugawara I., Zhang J., Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin // Indian Journal of experimental biology. 2009. V. 47. № 6. 520-522.
  17. Amikacin // Tuberculosis. 2008. V. 88. № 2. P. 87-88.
  18. Engstrcm A., Perskvist N., Werngren J. et al. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance inMycobacterium tuberculosis // J. Antimicrob. Chemother. 2011. V. 66. № 6. P. 1247-1254.
  19. Ajbani K., Rodrigues C., Shenai S. et al. Mutation and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India // J. Clin. Microbiol. 2011. V. 49. № 4. P. 1588-1590.
  20. Chakravorty S., Aladegbami B., Thoms K. et al. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in real-time PCR assay // J. Clin. Microbiol. 2011. V. 49. № 3. 932-940.
  21. Devasia R., Blackman A., Eden S. et al. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoruquinolone susceptibility // J. Clin. Microbiol. 2012. V. 50. № 4. P. 1390-1396.
  22. Piton J., Petrella S., Delarue M. et al. Stryctural insights into the quinolone resistance mechanism ofMycobacterium tuberculosis DNA gyrase // PLoS ONE. 2010. V. 5. № 8. P. 12245.
  23. Lienhardt C., Raviglione M., Spigelman M. et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future // The Journal of Infectious Diseases. 2012. V. 205. Suppl 2. P. 241-249.
  24. Veziris N., Ibrahim M., Lounis N. et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis // PLoS ONE. 2011. V. 6. № 3. P. 17556.
  25. Sarkar S., Suresh M. An overview of tuberculosis chemotherapy - a literature review // J. Pharm. Pharmaceut. Sci. 2011. V. 14. № 2. P. 148-161.
  26. Haagsma A., Abdillahi-Ibrahim R., Wagner M. et al. Selectivity of TMC207 towards mycobacterial ATPsynthase compared with that towards eukaryotic homologue // Antimicrobial agents and chemotherapy. 2009. V. 53. № 3.P. 1290-1292.
  27. Tawari N., Bairwa R., Ray M. et al. Design, synthesis and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents // FEBS J. 2012. V. 279. № 1. P. 113-125.
  28. Coban A., Deveci A. Y. Cayci et al. In vitro effect of tigecycline against Mycobacterium tuberculosis and a review of the available drugs for tuberculosis // Afr. J. Microbiol. Res. 2011. V. 5. № 3. P. 311-315.
  29. Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683 a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice // PLoS Medicine. 2006. V. 3. № 11. P. 466.
  30. Shehzad A., Rehman G., Ul-Islam M. et al. Challenges in the development of drugs for the treatment of tuberculosis // Braz. J. Infect. Dis. 2013. V. 17. № 1. P. 74-81.
  31. Ginsberg A., Laurenzi M., Rouse D. et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects // Antimicrob. Agents. Chemother. 2009. V. 53. № 9. P. 3720-3725.
  32. Goxon G., Craig D., Corrales R. et al. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues // PLoS ONE. 2013. V. 8. № 1. P. e53162.
  33. Diacon A., Dawson R., Hanekom M. et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients // Antimicrob. Agents. Chemother. 2010. V. 54. № 8. P. 3402-3407.
  34. Schecter G., Scott C., True L. et al. Linezolid in the treatment of multidrug-resistant tuberculosis // CID. 2010. V. 50. № 1. P. 49-55.
  35. Kaneko T., Cooper C., Mdluli K. Challenges and opportunities in developing novel drugs for TB // Future Med. Chem. 2011. V. 3. № 11. P. 1373-1400.
  36. Alfenaar J., van der Laan T., Simons S. et al. Susceptibility of clinical Mycobacterium tuberculosisisolates to a potentially less toxic derivate of linezolid, PNU-100480 // Antimicrob. Agents. Chemother. 2011. V. 55. № 3. P. 1287-1289.
  37. Tahlan K., Wilson R., Kastrinsky D. et al. SQ109 targets MmpL3, a membrane transporter of trehalosemonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis // Antimicrob. Agents. Chemother. 2012. V. 56. № 4. P. 1797-809.